Clinical Report: Aumolertinib in EGFR-Mutated NSCLC with Leptomeningeal Metastasis

Overview

This retrospective single-center study evaluated the safety and efficacy of aumolertinib in 79 patients with EGFR-mutated non-small cell lung cancer (NSCLC) and leptomeningeal metastasis (LM). Results demonstrated promising intracranial disease control and survival outcomes with manageable toxicity, supporting aumolertinib as a therapeutic option in this difficult-to-treat population.

Background

Leptomeningeal metastasis is a severe complication in NSCLC, particularly prevalent in patients harboring EGFR mutations, and is associated with poor prognosis and neurological decline. Conventional therapies have limited efficacy due to poor blood-brain barrier penetration. Third-generation EGFR-tyrosine kinase inhibitors (TKIs), such as osimertinib, have improved CNS penetration and outcomes. Aumolertinib, a third-generation EGFR-TKI developed in China, shows enhanced blood-brain barrier penetration and reduced toxicity, but real-world data on its effectiveness in LM are limited.

Data Highlights

Key Findings

• Aumolertinib demonstrated effective CNS penetration and activity in EGFR-mutated NSCLC patients with LM.
• Majority of patients (93.7%) received 110 mg/day dosing, with a small subset receiving 165 mg/day.
• Objective response and disease control rates were assessed using RECIST 1.1 and RANO-LM criteria, showing promising intracranial disease control.
• Median progression-free survival and overall survival were improved compared to historical data with first- or second-generation EGFR-TKIs.
• Adverse events were manageable, with toxicity reduced due to selective inhibition of mutant EGFR over wild-type.
• Real-world evidence from this largest-to-date cohort supports the clinical benefit of aumolertinib in this patient population.

Clinical Implications

Aumolertinib offers a viable treatment option for patients with EGFR-mutated NSCLC complicated by leptomeningeal metastasis, providing enhanced CNS disease control and survival benefits. Its favorable safety profile and BBB penetration make it suitable for managing this challenging condition. Clinicians should consider aumolertinib in patients with LM, especially those with T790M mutations or prior EGFR-TKI resistance.

Conclusion

This retrospective analysis confirms that aumolertinib is an effective and safe therapeutic agent for EGFR-mutated NSCLC patients with leptomeningeal metastasis, improving intracranial disease control and survival outcomes. Further prospective studies are warranted to validate these findings.

References

1. Zhang et al. 2023 -- Assessment of aumolertinib's safety and effectiveness in patients with EGFR-mutated NSCLC and leptomeningeal metastasis